| Age (years) | 69 ± 13.3 |
| Male sex (%) | 7 (63.6) |
| LVEF (%) | 31.6 ± 16.6 |
| Associated diagnosis (%) | |
| Arrhythmogenic right ventricular cardiomyopathy | 1 (9.1) |
| Acute myocardial infarction | 5 (45.5) |
| Dilated cardiomyopathy | 2 (18.2) |
| Chronic coronary artery disease | 3 (27.3) |
| Diabetes (%) | 4 (36.4) |
| ATP/shocks in 24 h before the first block (IQR) | 7 (4–12) |
| Refractory cardiac arrest (%) | 2 (18.2) |
| Cardiogenic shock (%) | 2 (18.2) |
| Septic shock (%) | 1 (9.1) |
| General anaesthesia (%) | 1 (9.1) |
| ICD recipients (%) | 1 (9.1) |
| Oral drugs at admission (%) | |
| β-blockers | 5 (45.4) |
| Class III AADs | 2 (18.2) |
| Anti-coagulant/anti-platelet therapy (%) | |
| None | 4 (36.4) |
| Acetylsalicylic acid | 4 (36.4) |
| DAPT | 2 (18.2) |
| Heparin for ECMO + DAPT | 1 (9.1) |
| In hospital death (%) | 4 (36.4) |
| Cardiogenic shock | 2 (18.2) |
| Cerebral death | 1 (9.1) |
| Massive pulmonary embolism | 1 (9.1) |
| VT ablation (%) | 3 (27.3) |
| Bilateral cardiac sympathetic denervation (%) | 1 (9.1) |
| Age (years) | 69 ± 13.3 |
| Male sex (%) | 7 (63.6) |
| LVEF (%) | 31.6 ± 16.6 |
| Associated diagnosis (%) | |
| Arrhythmogenic right ventricular cardiomyopathy | 1 (9.1) |
| Acute myocardial infarction | 5 (45.5) |
| Dilated cardiomyopathy | 2 (18.2) |
| Chronic coronary artery disease | 3 (27.3) |
| Diabetes (%) | 4 (36.4) |
| ATP/shocks in 24 h before the first block (IQR) | 7 (4–12) |
| Refractory cardiac arrest (%) | 2 (18.2) |
| Cardiogenic shock (%) | 2 (18.2) |
| Septic shock (%) | 1 (9.1) |
| General anaesthesia (%) | 1 (9.1) |
| ICD recipients (%) | 1 (9.1) |
| Oral drugs at admission (%) | |
| β-blockers | 5 (45.4) |
| Class III AADs | 2 (18.2) |
| Anti-coagulant/anti-platelet therapy (%) | |
| None | 4 (36.4) |
| Acetylsalicylic acid | 4 (36.4) |
| DAPT | 2 (18.2) |
| Heparin for ECMO + DAPT | 1 (9.1) |
| In hospital death (%) | 4 (36.4) |
| Cardiogenic shock | 2 (18.2) |
| Cerebral death | 1 (9.1) |
| Massive pulmonary embolism | 1 (9.1) |
| VT ablation (%) | 3 (27.3) |
| Bilateral cardiac sympathetic denervation (%) | 1 (9.1) |
AAD, anti-arrhythmic drugs; DAPT, double anti-platelet therapy; ECMO, extracorporeal membrane oxygenation; ICD implantable cardioverter-defibrillator; LVEF, left ventricular ejection fraction; VT, ventricular tachycardia.
| Age (years) | 69 ± 13.3 |
| Male sex (%) | 7 (63.6) |
| LVEF (%) | 31.6 ± 16.6 |
| Associated diagnosis (%) | |
| Arrhythmogenic right ventricular cardiomyopathy | 1 (9.1) |
| Acute myocardial infarction | 5 (45.5) |
| Dilated cardiomyopathy | 2 (18.2) |
| Chronic coronary artery disease | 3 (27.3) |
| Diabetes (%) | 4 (36.4) |
| ATP/shocks in 24 h before the first block (IQR) | 7 (4–12) |
| Refractory cardiac arrest (%) | 2 (18.2) |
| Cardiogenic shock (%) | 2 (18.2) |
| Septic shock (%) | 1 (9.1) |
| General anaesthesia (%) | 1 (9.1) |
| ICD recipients (%) | 1 (9.1) |
| Oral drugs at admission (%) | |
| β-blockers | 5 (45.4) |
| Class III AADs | 2 (18.2) |
| Anti-coagulant/anti-platelet therapy (%) | |
| None | 4 (36.4) |
| Acetylsalicylic acid | 4 (36.4) |
| DAPT | 2 (18.2) |
| Heparin for ECMO + DAPT | 1 (9.1) |
| In hospital death (%) | 4 (36.4) |
| Cardiogenic shock | 2 (18.2) |
| Cerebral death | 1 (9.1) |
| Massive pulmonary embolism | 1 (9.1) |
| VT ablation (%) | 3 (27.3) |
| Bilateral cardiac sympathetic denervation (%) | 1 (9.1) |
| Age (years) | 69 ± 13.3 |
| Male sex (%) | 7 (63.6) |
| LVEF (%) | 31.6 ± 16.6 |
| Associated diagnosis (%) | |
| Arrhythmogenic right ventricular cardiomyopathy | 1 (9.1) |
| Acute myocardial infarction | 5 (45.5) |
| Dilated cardiomyopathy | 2 (18.2) |
| Chronic coronary artery disease | 3 (27.3) |
| Diabetes (%) | 4 (36.4) |
| ATP/shocks in 24 h before the first block (IQR) | 7 (4–12) |
| Refractory cardiac arrest (%) | 2 (18.2) |
| Cardiogenic shock (%) | 2 (18.2) |
| Septic shock (%) | 1 (9.1) |
| General anaesthesia (%) | 1 (9.1) |
| ICD recipients (%) | 1 (9.1) |
| Oral drugs at admission (%) | |
| β-blockers | 5 (45.4) |
| Class III AADs | 2 (18.2) |
| Anti-coagulant/anti-platelet therapy (%) | |
| None | 4 (36.4) |
| Acetylsalicylic acid | 4 (36.4) |
| DAPT | 2 (18.2) |
| Heparin for ECMO + DAPT | 1 (9.1) |
| In hospital death (%) | 4 (36.4) |
| Cardiogenic shock | 2 (18.2) |
| Cerebral death | 1 (9.1) |
| Massive pulmonary embolism | 1 (9.1) |
| VT ablation (%) | 3 (27.3) |
| Bilateral cardiac sympathetic denervation (%) | 1 (9.1) |
AAD, anti-arrhythmic drugs; DAPT, double anti-platelet therapy; ECMO, extracorporeal membrane oxygenation; ICD implantable cardioverter-defibrillator; LVEF, left ventricular ejection fraction; VT, ventricular tachycardia.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
